Metlife Inc

Strong start to 2026 / “New Frontier” execution (good + surprising) - Adjusted earnings: $1.6B (+18% YoY) or $2.42/share (+23% YoY)—EPS growth outpaced earnings growth, reflecting disciplined capital management. - Adjusted premiums/fees & other revenues (ex pension risk transfers): +10% YoY, with broad-based growth across businesses/regions. - Adjusted ROE: 17% (top of 15–17% target range, well above cost of capital). - Expense discipline: Direct expense ratio 11.9%, improving vs last year and ahead of full-year target (they beat the 12.1% annual target).

Investment performance and variable income outlook (good, with some quarter-specific headwinds) - Pretax variable investment income (VII): $518M, third straight quarter above expectation, driven by private equity returns ~2.9% aided by strong venture capital. - Core vs total spread: total RIS investment spread 119 bps at top end of 100–120 bps guidance; core spread ex VII ~95 bps and down ~4 bps sequentially due to asset rotations from large Q4 inflows (esp. PRT-related flows). - RIS full-year guidance reaffirmed: expected full-year adjusted earnings $1.6B–$1.8B. - Q2 expectation: core spreads ~flat to modestly improved; total spreads continue to track full-year range, but flat yield curve / short-end higher remains a mild headwind.

Business momentum by segment (good + opportunities) - Group Benefits: $439M adjusted earnings (+19% YoY); sales +15%, adjusted PFOs +4%; working-age mortality exceptional (life mortality ratio 80.1% vs 2026 target range 83–88%). Persistency remains strong (persistency high 90s, tenure >20 years). - Retirement & Income Solutions (RIS): $451M (+11% YoY); $1.5B new sales (including UK-funded reinsurance and retail annuity reinsurance). - Asia: $487M (+31%); sales +22% constant currency—Japan sales +26% CC, Korea +44% CC; they cited new product traction and strong distribution. - EMEA: $110M (+33%), with adjusted PFOs +15% CC and sales +17% CC—reflecting multi-year shift toward capital-light A&H and life.